ELI LILLY & Co: Lilly to showcase new retatrutide, Taltz (ixekizumab) and Zepbound (tirzepatide) data at ACR Convergence 2026, advancing science at the intersection of rheumatologic conditions and obesity · Ereignisanalyse & Evidenz

BoerseAI

ELI LILLY & Co: Lilly to showcase new retatrutide, Taltz (ixekizumab) and Zepbound (tirzepatide) data at ACR Convergence 2026, advancing science at the intersection of rheumatologic conditions and obesity · Ereignisanalyse & Evidenz · BoerseAI

Ereignis wird geladen …